Verano Holdings (VRNO) Accounts Payables (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Accounts Payables of $29.0 million for Q1 2026, down 36.21% year-over-year from $45.4 million in Q1 2025, and down 25.24% quarter-over-quarter from $38.7 million in Q4 2025.
Verano Holdings (VRNO) Accounts Payables (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Accounts Payables for 6 consecutive years, with $29.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 36.21% year-over-year to $29.0 million; the TTM figure through Mar 2026 stood at $29.0 million (down 36.21% YoY), while the FY2025 annual figure was $38.7 million, down 2.98% from the prior year.
- Accounts Payables slipped to $29.0 million in Q1 2026 per VRNO's latest filing, from $38.7 million in the prior quarter.
- Across five years, Accounts Payables topped out at $60.8 million in Q2 2022 and bottomed at $25.2 million in Q2 2024.
- Historically, Accounts Payables has averaged $38.3 million across 5 years, with a median of $39.2 million in 2025.
- Annual changes were most pronounced in 2023 — Accounts Payables tumbled 42.91% — and 2025, when it soared 60.37%.
- Verano Holdings' Accounts Payables stood at $40.5 million in 2022, then declined by 22.76% to $31.3 million in 2023, then grew by 27.64% to $39.9 million in 2024, then decreased by 2.98% to $38.7 million in 2025, then retreated by 25.24% to $29.0 million in 2026.
- Business Quant data shows VRNO's Accounts Payables at $29.0 million in Q1 2026, $38.7 million in Q4 2025, and $42.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 356.00 Mn |
| 10 | Verano Holdings | 433.71 Mn | 348.51 Mn | 99.70 Mn | 26.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.52 Mn |
| Mar 31, 2026 | 28.96 Mn |
| Dec 31, 2025 | 38.74 Mn |
| Sep 30, 2025 | 42.32 Mn |
| Jun 30, 2025 | 39.67 Mn |
| Mar 31, 2025 | 45.40 Mn |
| Dec 31, 2024 | 39.93 Mn |
| Sep 30, 2024 | 42.49 Mn |
| Jun 30, 2024 | 25.20 Mn |
| Mar 31, 2024 | 28.31 Mn |
| Dec 31, 2023 | 31.28 Mn |
| Sep 30, 2023 | 31.02 Mn |
| Jun 30, 2023 | 34.73 Mn |
| Mar 31, 2023 | 30.52 Mn |
| Dec 31, 2022 | 40.50 Mn |
| Sep 30, 2022 | 52.21 Mn |
| Jun 30, 2022 | 60.83 Mn |
| Dec 31, 2021 | 45.17 Mn |